Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000457957 | SCV000556565 | benign | Tuberous sclerosis 2 | 2024-01-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001022472 | SCV001184215 | likely benign | Hereditary cancer-predisposing syndrome | 2019-02-09 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV001712427 | SCV001939952 | likely benign | not provided | 2020-02-10 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000457957 | SCV002039466 | benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002496805 | SCV002807044 | benign | Lymphangiomyomatosis; Isolated focal cortical dysplasia type II; Tuberous sclerosis 2 | 2022-05-27 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001712427 | SCV004129862 | likely benign | not provided | 2023-01-01 | criteria provided, single submitter | clinical testing | TSC2: BP4, BP7 |
Prevention |
RCV003915285 | SCV004730192 | likely benign | TSC2-related condition | 2023-03-08 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |